Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL4603178 | 0.83 | SLC18A3 (0.41) | SLC18A3 | |
| SCHEMBL463706 | 0.79 | SLC18A3 (0.58) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL11558939 | 0.79 | SLC18A3 (0.58) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL11558947 | 0.79 | SLC18A3 (0.58) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL11562664 | 0.79 | SLC18A3 (0.58) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL11562671 | 0.79 | SLC18A3 (0.58) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL11558271 | 0.78 | FUCA1 (0.60) | SLC18A3HTTFUCA1SIGMAR1ALDH1A1 | |
| SCHEMBL11558275 | 0.78 | FUCA1 (0.60) | SLC18A3HTTFUCA1SIGMAR1ALDH1A1 | |
| SCHEMBL11558282 | 0.78 | FUCA1 (0.60) | SLC18A3HTTFUCA1SIGMAR1ALDH1A1 | |
| SCHEMBL2241229 | 0.76 | SLC18A3 (0.55) | SLC18A3HTTCHRNA7SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | SLC18A3 649/4885HTT 567/4885CHRNA7 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.